

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Tae-Yoon Kim, *et al.* Art Unit: 1632
Serial No.: 10/589,102 Examiner: Noble
Filed: October 5, 2007
Entitled: THERAPEUTIC USE OF CPG OLIGODEOXYNUCLEOTIDE
FOR SKIN DISEASE

RESPONSE TO FINAL OFFICE ACTION MAILED AUGUST 5, 2009

EFS Web Filed
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being transmitted to the United States Patent and Trademark Office transmitted via the Office electronic filing system in accordance with 37 C.F.R. §1.6(a)(4).

Dated: November 5, 2009

By: /Michele R. Gilmer/

Michele R. Gilmer

Examiner Noble:

This communication is responsive to the Final Office Action mailed August 5, 2009, and setting a three-month period of response, ending November 5, 2009. Applicants include herein a Request for Continued Examination as provided under 37 CFR §1.114. Applicants respectfully request reconsideration of the application in view of the following remarks.

The Commissioner is hereby authorized to charge any fees during the entire pendency of this application, including fees due under 37 C.F.R. §§ 1.16 and 1.17 that may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-4302, referencing Attorney Docket No. SIGONG-13046. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

In accordance with the procedure for Amendment Practice under 37 C.F.R. §1.121, please amend the above-identified application as follows:

Listing of Claims begins on page 2 of this communication.

Remarks are on page 5 of this communication.